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ABSTRACT Visceral leishmaniasis is a neglected tropical disease that causes signiﬁ-
cant morbidity and mortality worldwide. Characterization of the pharmacokinetics
and pharmacodynamics of antileishmanial drugs in preclinical models is important
for drug development and use. Here we investigated the pharmacodynamics and
drug distribution of liposomal amphotericin B (AmBisome) in Leishmania donovani-
infected BALB/c mice at three different dose levels and two different time points af-
ter infection. We additionally compared drug levels in plasma, liver, and spleen in in-
fected and uninfected BALB/c mice over time. At the highest administered dose of
10 mg/kg AmBisome, 90% parasite inhibition was observed within 2 days after
drug administration, consistent with drug distribution from blood to tissue within 24
h and a fast rate of kill. Decreased drug potency was observed in the spleen when
AmBisome was administered on day 35 after infection, compared to day 14 after in-
fection. Amphotericin B concentrations and total drug amounts per organ were
lower in liver and spleen when AmBisome was administered at the advanced stage
of infection and compared to those in uninfected BALB/c mice. However, the magni-
tude of difference was lower when total drug amounts per organ were estimated.
Differences were also noted in drug distribution to L. donovani-infected livers and
spleens. Taken together, our data suggest that organ enlargement and other patho-
physiological factors cause infection- and organ-speciﬁc drug distribution and elimi-
nation after administration of single-dose AmBisome to L. donovani-infected mice.
Plasma drug levels were not reﬂective of changes in drug levels in tissues.
KEYWORDS biodistribution, drug potency, pharmacodynamics, visceral leishmaniasis
Visceral leishmaniasis (VL) is a vector-borne neglected tropical disease (NTD) causedby protozoan parasites of the genus Leishmania. VL has a high mortality rate if
untreated. Current estimates suggest 200,000 to 400,000 cases and 20,000 to 40,000
deaths per year worldwide, with over 90% of cases occurring in India, Bangladesh,
Sudan, South Sudan, Brazil, and Ethiopia (1).
Major clinical manifestations of disease are fever, enlargement of the liver and
spleen, weight loss, and pancytopenia. Available treatment options include pentavalent
antimonials, paromomycin in combination with pentavalent antimony (in East Africa),
miltefosine and amphotericin B in different formulations (2). Liposomal amphotericin B
(AmBisome) has emerged as the preferred treatment for VL in Europe and the United
States (3) and South Asia (2). In India, a cure rate of 95.7% was achieved with a single
infusion of 10 mg/kg of AmBisome in a trial carried out at an urban referral center (4).
The feasibility of this treatment regimen was conﬁrmed in a rural setting in Bangladesh
at the primary health care level (5). Single-dose AmBisome was also one component in
a recent trial of short-course multidrug treatment regimens for VL in India (6).
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AmBisome was initially developed to improve efﬁcacy and reduce toxicity of am-
photericin B as an antifungal agent. Its favorable therapeutic index is attributed to
prolonged circulation times due to a small liposome size, allowing distribution to
tissues, and a tight association of amphotericin B with the liposome bilayer, providing
stability under physiological conditions (7). AmBisome also remains the antileishmanial
agent with the widest therapeutic window for treatment of VL (3).
Earlier studies have established the preclinical pharmacokinetics (PK) of AmBisome
in mice, rats, rabbits, and dogs (7, 8). In addition, a comparative, single-time-point
biodistribution study in Leishmania donovani-infected and uninfected BALB/c mice
showed that amphotericin B concentrations in liver and spleen were lower in infected
mice after intravenous (i.v.) administration of AmBisome (9). A separate study showed
that AmBisome, when administered as a single dose to L. donovani-infected BALB/c
mice, was less effective in the chronic stage of infection compared to the acute stage
(10). In anti-infective therapy with drugs that directly kill pathogens, such as ampho-
tericin B, drug efﬁcacy is driven by infection site-speciﬁc drug concentrations (11, 12).
We therefore hypothesized that the decrease in potency of AmBisome observed in
chronic experimental VL (EVL) is linked to a decrease in organ-speciﬁc drug concen-
trations associated with progression of infection. Here we show that (i) decreased
potency of AmBisome during progressive EVL is most pronounced in the spleen, (ii)
total drug amounts in liver and spleen progressively decrease during EVL, (iii) organ-
speciﬁc drug distribution and elimination patterns occur in EVL, and (iv) changes in
drug levels in tissues are not reﬂected in the blood compartment.
RESULTS
Efﬁcacy of single-dose liposomal amphotericin B in L. donovani-infected
BALB/c mice at two different time points after infection. Single-dose AmBisome was
administered at doses of 10, 2.5, and 0.6 mg/kg of body weight 14 or 35 days after
infection. Parasite burden was evaluated 7 days after dosing. A reproducible decrease
in drug efﬁcacy between day 21 and day 42 postinfection was noted in the spleen,
which was more pronounced at the lower doses. In the liver, decreased drug efﬁcacy
at the lower two doses was noted in one experiment, whereas in another experiment,
an increase in drug efﬁcacy was observed at the lowest dose (Table 1).
Time-kill studies. Single-dose AmBisome was administered to L. donovani-infected
BALB/c mice 14 days after infection at doses of 10, 2.5, and 0.6 mg/kg. Parasite burden
TABLE 1 Efﬁcacy of single-dose AmBisome in L. donovani-infected BALB/c micea
Parameter
Dose
(mg/kg)
Result for parameter shown
Liver Spleen
Day 21
p.i.
Day 42
p.i. Signiﬁcance
Day 21
p.i.
Day 42
p.i. Signiﬁcance
% of reduction in parasite burden
Expt 1 10 99 0 98 1 NS 99 0 83 4 P 0.05
2.5 78 2 78 5 NS 53 6 5 5 P 0.0001
0.6 21 8 41 4 P 0.01 44 6 4 4 P 0.0001
Expt 2 2.5 81 2 80 3 NS 71 2 36 11 P 0.05
Expt 3 10 100 0 99 1 NS 99 0 93 2 NS
2.5 94 1 80 5 P 0.05 40 6 45 7 NS
0.6 54 3 22 7 P 0.0001 38 10 16 9 NS
Parasite burden (LDU) in
untreated control groups
Expt 1 NA 966 66 518 48 P 0.01 88 8 118 15 NS
Expt 2 NA 415 32 176 11 P 0.001 18 1 53 8 P 0.01
Expt 3 NA 682 54 194 44 P 0.001 18 2 84 9 P 0.001
aParasite burden was evaluated 7 days after drug administration on day 21 or 42 postinfection (p.i.). Data are presented as mean  SEM. NS, not signiﬁcant; NA, not
applicable; LDU, Leishman-Donovan units.
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was evaluated 1, 2, 3, or 7 days after dosing. In the liver, effective parasite kill (90%
inhibition) was observed 2 days after administration of the highest dose. At the dose of
2.5 mg/kg, the hepatic parasite burden was inhibited by 60% at 2 days, 70% at 3
days, and 80% (maximum kill) at 7 days after drug administration. The dose of 0.6
mg/kg was ineffective (40% inhibition), and no change in parasite kill was observed
over time (Fig. 1A). A similar pattern of effective kill was observed in the spleen after
administration of 10 mg/kg AmBisome (80% and 90% inhibition in repeat experi-
ments at 2 days and 90% inhibition at 3 days after drug administration), and a static
pattern (40% inhibition) was observed after administration of 0.6 mg/kg. Maximum
kill at the dose of 2.5 mg/kg varied from 57 to 71% inhibition in repeat experiments,
with peaks at 2 and 3 days after drug administration (Fig. 1B). In an additional
experiment, L. donovani-infected BALB/c mice were treated with a single dose of 2.5
mg/kg AmBisome 33 days after infection. The hepatic parasite burden was inhibited by
55, 67, and 62%, respectively, on days 1, 2, and 3 after drug administration. In the
spleen, parasite kill was low on day 1 after drug administration (40% inhibition) and
increased on days 2 and 3 after drug administration to a maximum of 46% inhibition
(Fig. 1C).
Plasma pharmacokinetics of single-dose AmBisome in L. donovani-infected
BALB/c mice. Single-dose AmBisome was administered at dose levels of 10, 2.5, and 0.6
mg/kg 14 days after infection. Plasma samples were obtained at 5 and 30 min and 1,
3, 6, and 24 h after drug administration, followed by determination of drug concen-
trations and estimation of PK parameters. The volume of distribution (V) and clearance
(CL) increased with decreasing doses of AmBisome. The V increased from 104 ml/kg at
10 mg/kg to 252 and 681 ml/kg at 2.5 mg/kg and 0.6 mg/kg, respectively. CL was 27
FIG 1 Time to kill of single-dose AmBisome in L. donovani-infected BALB/c mice. (A and B) Percentages of inhibition
of parasite burden in liver (A) and spleen (B) 1, 2, 3, and 7 days after a single dose of AmBisome at dose levels of
10 mg/kg (black bars), 2.5 mg/kg (gray bars), and 0.6 mg/kg (striped bars). (C) Percentage of inhibition of parasite
burden in liver (black bars) and spleen (gray bars) 1, 2, and 3 days after a single dose of 2.5 mg/kg AmBisome.
Treatment was given 14 days (A and B) or 33 days (C) after infection. Data are presented as group mean (n  5),
and error bars represent the standard error of the mean (SEM). Data in panels A and B are representative of two
separate experiments.
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ml/h/kg at a dose of 10 mg/kg and 48.1 and 41.9 ml/h/kg at doses of 2.5 and 0.6 mg/kg.
The area under the concentration-time curve from 0 to 24 h (AUC0–24) was highest at
10 mg/kg (368.5 h · g/ml) and lower at doses of 2.5 mg/kg and 0.6 mg/kg (50.5 and
10.8 h · g/ml, respectively). PK parameters are summarized in Table 2.
Tissue distribution of amphotericin B in L. donovani-infected BALB/c mice
following administration of AmBisome at two different time points after infec-
tion. Single-dose AmBisome was administered 14 or 35 days after infection. Ampho-
tericin B concentrations in plasma, liver, and spleen were measured 7 days after dosing.
Lower amphotericin B concentrations were observed in livers and spleens when equal
drug doses were administered on day 35 compared to day 14 postinfection. When
expressed as nanograms per gram of tissue, drug concentrations in the liver were 2.6-,
2.2-, and 5.6-fold lower, respectively, on day 42 compared to day 21 postinfection at
AmBisome doses of 10, 2.5, and 0.6 mg/kg. Respective tissue concentrations in the
spleen were 4.5-, 2.8-, and 9.6-fold lower, respectively. Statistical signiﬁcance was noted
for the 10-mg/kg dose group (P  0.0001 for liver and P  0.01 for spleen). Organ
weights signiﬁcantly increased from day 21 to day 42 postinfection (P  0.0001 in all
dose groups), with a 1.5-fold increase in the liver and 2.3- to 2.9-fold increases in the
spleen. When taking these increases in organ weights into account and estimating the
total drug amount per organ, the difference between amphotericin B concentrations on
day 21 and day 42 postinfection decreased. Differences in total amphotericin B
amounts per organ at AmBisome doses of 10, 2.5, and 0.6 mg/kg, respectively, were
1.7-, 1.5-, and 3.8-fold in the liver and 1.5-, 1.3-, and 3.9-fold in the spleen. Statistical
signiﬁcance was noted for the 10-mg/kg dose group in the liver (P  0.0001). Overall,
higher amphotericin B concentrations were measured in the liver compared to the
spleen. Data are summarized in Table 3. Amphotericin B concentrations in plasma
remained unchanged when drug was administered on day 14 compared to day 35
postinfection. A 0.3-fold difference was noted in the 0.6-mg/kg dose group but was not
statistically signiﬁcant (Table 4).
Comparative amphotericin B plasma and tissue concentrations in L. donovani-
infected and uninfected BALB/c mice 7 days after administration of single-dose
AmBisome. Amphotericin B concentrations were measured in L. donovani-infected (14
or 35 days after infection) and age- and husbandry-matched uninfected BALB/c mice
after administration of 2.5 mg/kg AmBisome. At both time points, amphotericin B
concentrations were signiﬁcantly lower (P  0.0001) in livers and spleens from infected
BALB/c mice compared to uninfected ones. In the liver, mean drug concentrations (ng
amphotericin B/g tissue) on days 21 and 42 postinfection, respectively, were 3.5- and
6.5-fold lower in infected compared to uninfected BALB/c mice. This translated into 2.5-
and 5.4-fold differences when taking organ weights into account and estimating the
total amount of amphotericin B per organ (Fig. 2A and B). In the spleen, mean
amphotericin B concentrations were 29.3- and 100.9-fold lower, respectively, in infected
compared to uninfected mice on days 21 and 42 postinfection. Respective organ
weight adjusted differences were 10.3- and 16.5-fold (Fig. 2C and D). The opposite was
TABLE 2 Pharmacokinetic proﬁle of single-dose AmBisome in plasma of L. donovani-
infected BALB/c micea
Parameter
Result for parameter at single i.v. dose shown
10 mg/kg 2.5 mg/kg 0.6 mg/kg
t1/2 (h) 3.4 5.0 NQ
Tmax (h) 0.08 0.08 0.08
Cmax (g/ml) 240.3 29.8 3.3
AUClast (h · g/ml) 368.5 50.5 10.8
CL (ml/h/kg) 27.0 48.1 41.9
V (ml/kg) 104 252 681
aMice had been infected for 14 days at the time of dosing. The parasite burdens in untreated controls
(mean  SD) were 644  25 LDU in the liver and 17  1 LDU in the spleen (n  3). Data are
representative of two separate experiments (n  1 mouse/time point). NQ, not quoted.
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observed in plasma, and signiﬁcantly higher amphotericin B concentrations were
measured in infected BALB/c mice compared to uninfected ones, with 2- and 1.9-fold
differences, respectively, on day 21 (P 0.01) and day 42 (P 0.001) postinfection (Fig.
2E). Tabulated results are provided in Table S1 in the supplemental material.
To investigate if differences in amphotericin B levels were also observed after
administration of higher drug doses, L. donovani-infected (day 33 postinfection) or
uninfected BALB/c mice were treated with a single dose of 40 mg/kg AmBisome. In line
with the above results, amphotericin B concentrations were signiﬁcantly lower (P 
0.0001) in livers and spleens from infected BALB/c mice compared to uninfected ones.
However, plasma drug concentrations were similar between the two different groups
(P  0.05). Data are shown in Table S1.
Comparative amphotericin B plasma and tissue concentrations in L. donovani-
infected and uninfected BALB/c mice up to 48 h after administration of single-
dose AmBisome. A single dose of 2.5 mg/kg AmBisome was administered to L.
donovani-infected mice (day 33 postinfection) and age- and husbandry-matched un-
infected BALB/c mice. Plasma and tissue samples were collected 5 min and 4, 24, and
48 h after drug administration, and amphotericin B concentrations were determined.
Plasma amphotericin B levels decreased within 24 h in uninfected and L. donovani-
TABLE 3 Tissue concentrations of amphotericin B in L. donovani-infected BALB/c mice 7 days after administration of single-dose
AmBisomea
Parameter and AmBisome
treatment group
Result for parameter at AmBisome dose shown
Liver Spleen
Ratio for day
21 vs 42 p.i.
Signiﬁcance for day 21
vs 42 p.i.
Day 21 p.i. Day 42 p.i. Day 21 p.i. Day 42 p.i. Liver Spleen Liver Spleen
Amphotericin B concn
(ng/g tissue) at dose:
10 mg/kg 115,733 19,582 44,232 6,900 19,233 8,600 4,266 1,399 2.6 4.5 P 0.0001 P 0.01
2.5 mg/kg 12,220 1,308 5,492 862 1,770 412 624 205 2.2 2.8 NS NS
0.6 mg/kg 1,430 923 257 58 490 146 51 12 5.6 9.6 NS NS
Organ wt (mg) at dose:
10 mg/kg 998 79 1,532 98 170 35 492 66 0.7 0.3 P 0.0001 P 0.0001
2.5 mg/kg 1,068 51 1,544 86 288 29 654 70 0.7 0.4 P 0.0001 P 0.0001
0.6 mg/kg 1,070 82 1,580 67 286 23 698 50 0.7 0.4 P 0.0001 P 0.0001
Estimated amt of amphotericin
B (ng/organ) at dose:
10 mg/kg 114,548 12,631 67,456 9,000 3,071 699 2,046 455 1.7 1.5 P 0.0001 NS
2.5 mg/kg 12,907 1,308 8,494 1,504 522 79 417 171 1.5 1.3 NS NS
0.6 mg/kg 1,524 985 404 85 138 29 35 8 3.8 3.9 NS NS
aAmphotericin B concentrations were determined 7 days after drug administration on day 21 or day 42 postinfection (p.i.) in livers and spleens (this table) and plasma
(Table 4). Data are presented as group mean (n  5 mice/group)  SD. Ratios were calculated as the ratio of the mean drug concentration at day 21 p.i. to the
mean drug concentration at day 42 p.i. Total amphotericin B concentrations per organ were calculated for individual mice as follows: organ weight in grams (as
determined at sacriﬁce)  amphotericin B concentration in nanograms per gram of tissue (as measured after processing of whole organs). NS, not signiﬁcant. The
drug concentrations presented here were determined in the same samples used to evaluate drug potency in experiment 3 in Table 1.
TABLE 4 Plasma concentrations of amphotericin B in L. donovani-infected BALB/c mice 7
days after administration of single-dose AmBisomea
AmBisome
treatment group
Plasma amphotericin B
concn (ng/ml plasma)
Ratio for day
21 vs 42
Signiﬁcance for
day 21 vs 42Day 21 Day 42
10 mg/kg 191 23 216 47 0.9 NS
2.5 mg/kg 116 18 129 28 0.9 NS
0.6 mg/kg 5 5 16 9 0.3 NS
aAmphotericin B concentrations were determined 7 days after drug administration on day 21 or day 42
postinfection (p.i.) in livers and spleens (Table 3) and plasma (this table). Data are presented as group mean
(n  5 mice/group)  SD. Ratios were calculated as the ratio of the mean drug concentration at day 21 p.i.
to the mean drug concentration at day 42 p.i. NS, not signiﬁcant.
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FIG 2 Comparative plasma and tissue drug concentrations in L. donovani-infected and uninfected BALB/c mice 7 days after
administration of single-dose AmBisome. Amphotericin B (AmB) concentrations were measured on day 21 or day 42 postinfection and
in uninfected BALB/c mice, maintained under identical conditions. Amphotericin B concentrations are presented as nanograms per
gram of tissue (A and C) or nanograms per organ (B and D) in livers (A and B) and spleens (C and D) and as nanograms per milliliter
in plasma (E). Each symbol represents data from an individual mouse. Horizontal lines indicate the mean (n  4 to 5 mice/group) and
error bars the standard deviation (SD). Total amphotericin B concentrations per organ were calculated for individual mice as follows:
organ weight in grams (as determined at sacriﬁce)  amphotericin B concentration in nanograms per gram of tissue (as measured
after processing of whole organs). Tissue concentrations in infected mice were measured in samples from experiment 3 in Table 1.
Data are representative of two separate experiments.
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infected BALB/c mice and remained at similar levels at 24 and 48 h after drug
administration (Fig. 3A and B). An increase in amphotericin B concentration was
observed in livers and spleens of uninfected BALB/c mice from 5 min to 4 h after drug
administration. Amphotericin B concentrations at 24 and 48 h after drug administration
were comparable to those measured at 4 h (Fig. 3C and E). A different kinetic was
observed in L. donovani-infected BALB/c mice. In the liver, a small increase in ampho-
tericin B concentration was noted from 5 min to 4 h after drug administration, followed
by a decrease at 24 h and, most notably, 48 h after drug administration (Fig. 3D). In the
spleen, amphotericin B concentrations decreased over the whole observation period,
with no increase noted (Fig. 3F). Similar kinetics were observed when estimating total
amount of drug per organ (Fig. 3G to J). Tabulated results are provided in Table S2 in
the supplemental material.
Host responses to infection. Serum samples from L. donovani-infected (days 14
and 43 postinfection) and age- and husbandry-matched uninfected BALB/c mice were
subjected to electrophoresis and protein determination. Signiﬁcant differences (P 
0.05) in serum protein proﬁles were identiﬁed. In infected BALB/c mice, serum
concentrations of total protein (46.8  0.6 versus 56.6  1.0 g/liter), alpha globulin
(6.7  0.2 versus 8.5  0.2 g/liter), and gamma globulin (7.6  0.2 versus 16.1  1.0
g/liter; 16.3%  0.5% versus 28.4%  1.3%) increased from day 14 to day 43
postinfection. At the same time, percentages of albumin decreased (61.4%  0.7%
versus 49.3%  1.1%), but no signiﬁcant difference was found when comparing total
albumin levels. The albumin/globulin ratio decreased from day 14 to day 43 postin-
fection (1.6  0.0 versus 1.0  0.0). Compared to uninfected BALB/c mice, higher levels
of total protein (56.6  1.0 versus 47.6  0.8 g/liter), alpha globulin (8.5  0.2 versus
7.3 0.2 g/liter), and gamma globulin (16.1 1.0 versus 6.5 0.2 g/liter; 28.4% 1.3%
versus 13.6%  0.2%) were measured in L. donovani-infected mice on day 43 postin-
fection. At the same time point, infected BALB/c mice had lower levels of albumin
(27.8  0.4 versus 29.9  0.5 g/liter; 49.3%  1.1% versus 62.8%  1.6%) than
uninfected ones. On day 14 postinfection, increased percentages of gamma globulin
were noted in infected compared to uninfected BALB/c mice (16.3%  0.5% versus
12.3%  0.6%). On day 43 postinfection, infected BALB/c mice had a lower albumin/
globulin ratio than uninfected ones (1.0  0.0 versus 1.7  0.1). Data are summarized
in Table 5.
DISCUSSION
The pharmacodynamics (PD) and pharmacokinetics (PK) of current antileishmanial
drugs have yet to be fully established in preclinical disease models. Here we investi-
gated the potency and biodistribution of liposomal amphotericin B (AmBisome) in EVL
after administration of three different single doses and at two different time points.
AmBisome was well tolerated at all doses administered, and no signs of drug toxicity
were noted, based on observations of weight, fur condition, behavior, and facial
expression. We also determined the PK proﬁle of AmBisome in plasma of L. donovani-
infected BALB/c mice in an exploratory study and compared trends to published data
in uninfected mice. The observed increase in maximum concentration of drug in serum
(Cmax) and AUClast and the decrease in V and CL with increasing doses are in line with
these data (7).
After infection of BALB/c mice with L. donovani, the parasite burden in the liver
rapidly increases for the ﬁrst 2 to 4 weeks, followed by a decrease in parasite numbers
and resolution of infection. In the spleen, the parasite burden increases from 2 weeks
after infection and parasite persistence is observed (13–15). Consideration of this
organ-speciﬁc pattern of parasite growth is important when analyzing drug efﬁcacy
and potency data. In the spleen, drug efﬁcacy was evaluated against an increasing
parasite burden at both time points, and a decrease in potency was observed when
drug was administered on day 35 compared to day 14 postinfection. However, the
magnitude of decrease and the dose at which this occurred differed between experi-
ments. It is notable that the decrease in drug concentrations/total drug amounts in the
AmBisome Pharmacodynamics and Biodistribution in EVL Antimicrobial Agents and Chemotherapy
September 2017 Volume 61 Issue 9 e00497-17 aac.asm.org 7
 o
n
 N
ovem
ber 22, 2017 by London School of Hygiene & Tropical M
edicine
http://aac.asm
.org/
D
ow
nloaded from
 
FIG 3 Comparative plasma and tissue drug concentrations in L. donovani-infected and uninfected BALB/c mice up
to 48 h after administration of single dose AmBisome. AmBisome was administered to BALB/c mice, naive (A, C, E,
G, and I) or infected with L. donovani for 33 days (B, D, F, H, and J), and amphotericin B (AmB) concentrations were
determined in plasma (A and B), liver (C, D, G, and H), and spleen (E, F, I, and J) at 5 min and 4, 24, or 48 h after drug
administration. Amphotericin B concentrations are presented as nanograms per gram of tissue (C to F) or total
amphotericin B concentration per organ (G to J). Total amphotericin B concentrations per organ were calculated as
follows: organ weight in grams (as determined at sacriﬁce)  amphotericin B concentration in nanograms per gram
of tissue (as measured after processing of whole organs). Each symbol represents data from an individual mouse.
Horizontal lines indicate the mean (n  3/group) and error bars the standard deviation (SD).
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spleen following administration of the same dose of AmBisome on day 14 versus day
35 postinfection was less pronounced in the third compared to the second experiment
presented in Table 1 (see Table S3 in the supplemental material). This may explain the
lack of decreased drug potency observed in experiment 3. In the liver, opposing trends
were observed at the lowest dose. However, data obtained in the liver on day 42
postinfection are not indicative of direct drug kill only: the data reﬂect a mixture of
parasite killing by drug and a mature granulomatous host response resolving the
infection (16–18). Hence, these opposing trends at a dose that lacked meaningful
antileishmanial drug efﬁcacy likely reﬂect differences in the efﬁciency of host response
rather than in drug potency.
In parallel to evaluating drug potencies, we determined amphotericin B concen-
trations in plasma, livers, and spleens of infected BALB/c mice at the two different
time points and estimated the total drug amount per organ. In livers and spleens,
lower drug concentrations and total drug amounts per organ were noted when
drug was administered on day 35 compared to day 14 postinfection, and the
difference was highest at the lowest dose. The magnitude of difference was lower
for absolute (organ weight adjusted) values than for relative values, which suggests
that differences in drug levels between the two time points can partly be explained
by the infection-associated increase in organ weights. A combined effect of organ
enlargement and other pathology-associated factors on drug distribution following
administration of AmBisome to L. donovani-infected BALB/c mice is also supported by
comparative studies in infected and uninfected mice. Again the magnitude of decrease
in amphotericin B levels in livers and spleens of infected mice was lower when organ
weight adjustment was applied but remained signiﬁcant and increased from day 21 to
day 42 postinfection in both organs. Interestingly, plasma levels of amphotericin B were
higher in infected compared to uninfected mice at this point.
To gain further insight into the kinetics of parasite kill and drug distribution, we next
examined drug potency and distribution at multiple and earlier time points after drug
administration. The highest dose of 10 mg/kg AmBisome exerted maximum kill within
48 h of drug administration. This window of time is consistent with the drug distribu-
TABLE 5 Serum protein proﬁle in L. donovani-infected and uninfected BALB/c micea
Parameter
Result for parameter shown
Day 14 Day 43
Infected Uninfected Infected Uninfected
Total protein (g/liter) 46.8 0.6 A 46.2 0.6 56.6 1.0 AB 47.6 0.8 B
Albumin
g/liter 28.7 0.4 29.5 0.6 27.8 0.4 B 29.9 0.5 B
% 61.4 0.7 A 64.0 1.1 49.3 1.1 AB 62.8 1.6 B
Alpha globulin
g/liter 6.7 0.2 A 6.8 0.2 8.5 0.2 AB 7.3 0.2 B
% 14.4 0.3 14.7 0.4 15.1 0.3 15.3 0.3
Beta globulin
g/liter 3.7 0.3 4.2 0.4 4.1 0.1 4.0 0.8
% 7.9 0.5 9.0 0.7 7.2 0.2 8.2 1.6
Gamma globulin
g/liter 7.6 0.2 A 5.7 0.3 16.1 1.0 AB 6.5 0.2 B
% 16.3 0.5 AC 12.3 0.6 C 28.4 1.3 AB 13.6 0.2 B
Albumin/globulin ratio 1.6 0.0 A 1.8 0.1 1.0 0.0 AB 1.7 0.1 B
aBALB/c mice (n  6 or 7/group) were infected with L. donovani for 14 days or 43 days or left uninfected
but maintained under identical conditions to infected mice. Data are presented as mean  SEM. The
parasite burdens (mean  SD) in infected livers were 396  61 and 273  52 LDU on days 14 and 43
postinfection, respectively, and those in infected spleens were 8  2 and 93  18 LDU, respectively. Values
indicated with the same letter (A, B, or C) are signiﬁcantly different (P  0.05).
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tion from blood to tissues within 24 h of drug administration, also observed in
uninfected mice and other disease models (19, 20), and a high rate of parasite kill.
Differences in amphotericin B levels between L. donovani-infected and uninfected
tissues were also observed at earlier time points. Importantly, these were indicative of
organ-speciﬁc drug distribution and elimination in EVL. Most notable was a lack of drug
accumulation over time in L. donovani-infected spleens. It is currently not known to
what extent the liposomal formulation contributes to the observed differences. Com-
parative biodistribution studies between single-dose AmBisome and Fungizone, an-
other clinically used nonliposomal amphotericin B formulation, are hampered by the
toxicity of Fungizone. The maximum tolerated dose of 1 mg/kg (intravenous [i.v.] bolus
administration) of this formulation precludes dosing at clinically meaningful dose levels
(21).
Changes in drug distribution under pathological conditions have been reported for
a number of antimicrobials (9, 11, 12, 20, 22–25), and increased drug concentrations at
inﬂammatory sites are believed to result from capillary endothelial damage and re-
cruitment of drug-containing phagocytic cells to sites of infection. However, tissue
penetration of drugs is governed by a number of factors, which include drug formu-
lation, plasma protein binding, and underlying disease (12). In EVL, different patho-
physiological features are observed in the liver and spleen. In the liver, a Th1-
dominated granulomatous response is characterized by an inﬂux of T cells, B cells, NK
cells, and monocytes, with a peak in the inﬂammatory response around 4 weeks after
infection (16–18). Kupffer cells (KCs), which in uninfected mice line the sinusoids and
form a uniformly distributed phagocytic network, are recruited into the core of the
granuloma in infected mice. Isolated KCs remaining in the sinusoidal network of
infected mice have a reduced cell volume (26), and loss of membrane activity of KCs has
been reported within 2 h of infection with L. donovani (27). Infection of the spleen is
characterized by a breakdown of marginal zone architecture, loss of marginal zone
macrophages (MZMs) and repositioning of marginal metallophilic macrophages
(MMMs) (28), an increase in the number of red pulp macrophages (29), destruction
of the follicular dendritic cell and the gp38 ﬁbroblastic reticular cell networks (13),
and substantial changes to the vascular network, including sprouting of -SMA
vessels with active endothelial cell proliferation (30).
Following intravenous administration, liposomes interact with blood proteins, and
an inverse relationship between the amount of protein bound and liposome clearance
rate from blood has been demonstrated (31). Here we show that chronically infected
BALB/c mice display an increase in serum gamma globulin and, to a lesser extent, alpha
globulin and a decrease in albumin. Some of these proteins have been implicated in
lipid-protein interactions (32, 33), which may account for different rates in the
distribution of AmBisome from blood to tissues between infected and uninfected
mice. From the bloodstream, liposomes distribute to highly perfused tissues such as
the liver and spleen, which regulate drug elimination (32), and cells of the mono-
nuclear phagocyte system (MPS) play a major role in this distribution (34). In the
liver also hepatocytes can participate in the uptake and metabolism of small and
phosphatidylcholine-based liposomes (35, 36), which is linked to their ability to exit
fenestrated vessels in this organ (32). In uninfected mice, the diameter of liver sinu-
soidal endothelial cell (LSEC) fenestrae is on average 99  18 nm (37), which would
allow AmBisome with a mean diameter of 100 nm (7) to pass through. However,
fenestrae are dynamic structures, which may undergo changes in response to local
external stimuli (37), and the impact of L. donovani infection on fenestration is as yet
unknown. In the spleen of uninfected mice, most of the blood ﬂows through the
marginal zone (38), and MZMs display preferential uptake of clodronate liposomes over
other phagocytic cells in the spleen (39). It is currently unknown if there are also
differences in the extent of drug uptake between the different cell types for AmBisome.
Future studies, utilizing advanced techniques to simultaneously image drug and cells,
are needed to shed light on the spatial distribution of drug in healthy and diseased
organs over time (40).
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Gershkovich et al. (9) hypothesized that reduced phagocytic activity of macrophages
in EVL or increased drug elimination, either through leaking capillaries in inﬂamed
tissue or binding of drug to fragments of killed parasites, may explain the differences
in drug levels between infected and uninfected tissues. While the latter hypothesis
cannot be ruled out, it is unlikely to fully account for the lack of drug accumulation in
the spleen. Our data favor a model in which (i) increases in organ mass lead to
decreased total drug amounts/organ, (ii) increased elimination and/or metabolism is
the predominant feature in the liver, and (iii) drug distribution to the spleen is
progressively decreased during EVL.
A retrospective analysis of risk factors for VL relapse following treatment of patients
in India with 20 mg/kg AmBisome, administered as 4 doses of 5 mg/kg, showed that a
slower decrease in splenomegaly during treatment, but not spleen size at admission,
was signiﬁcantly associated with relapse (41). In L. donovani-infected BALB/c mice, the
granulomatous response in the liver appears to follow many of the characteristics
observed in subclinical human infection, whereas the spleen shows hallmarks of
progressive human disease (42). However, it is currently unknown if the differences we
observed in AmBisome distribution and elimination in this experimental model also
exist at different stages in human VL. Nonetheless, understanding the mechanisms of
how the pathophysiology of EVL affects drug absorption, distribution, metabolism, and
elimination (ADME) will improve the development and use of antileishmanial drugs and
drug delivery systems.
MATERIALS AND METHODS
Drugs and reagents. AmBisome was purchased from Gilead (Cambridge, United Kingdom). The
powder was reconstituted in sterile water following the manufacturer’s directions, and further dilutions
were prepared in 5% glucose. Amphotericin B (Vetranal analytical standard), tolbutamide, dimethyl
sulfoxide (DMSO), and sodium dodecyl sulfate (SDS) were obtained from Sigma, United Kingdom, and
heparin was obtained from John Bell & Croyden, United Kingdom. Methanol (high-performance liquid
chromatography [HPLC] grade), 0.1% (vol/vol) formic acid in water (liquid chromatography-mass spec-
trometry [LC-MS] grade), and water (LC-MS grade) were purchased from Fisher Scientiﬁc UK, Ltd., United
Kingdom.
In vivo experiments and treatment. Female BALB/c (Charles River, United Kingdom) and Rag-1 (B6)
knockout (KO) mice (London School of Hygiene & Tropical Medicine [LSHTM] breeding colony) were
maintained under speciﬁc-pathogen-free conditions in individually ventilated cages and exposed to
12-h-light–12-h-dark cycles. Standard rodent diet (RM no. 1 expanded) and ﬁltered tap water were
supplied ad libitum. Mice (6 to 10 weeks of age at the start of experiments) were infected by intravenous
(i.v.) injection of 2  107 parasites (L. donovani MHOM/ET/67/HU3) as described previously (43). Parasites
were maintained in Rag-1 (B6) KO mice, and amastigotes were harvested from spleens 40 days after
infection. BALB/c mice were treated either 14 or 35 days after infection with a single i.v. dose of
AmBisome in a 0.2-ml bolus injection. On the day of treatment, prior to the administration of drugs, mice
were weighed and randomized into the different treatment groups using a random number generator.
The average weight of mice in each experiment was used for dose calculations. Untreated groups of mice
were included as controls where appropriate. Age-matched uninfected mice were maintained under
identical conditions for the same length of time as their infected comparators. At experimental
endpoints, mice were weighed and humanely killed by exsanguination under terminal anesthesia.
Blood was collected by cardiac puncture in Eppendorf tubes containing heparin, and plasma was
harvested by centrifugation. Livers and spleens were removed, and their weight was recorded.
Plasma and tissue samples were stored at 80°C until further processing. For determination of
parasite burdens, tissue impression smears were prepared, ﬁxed in 100% methanol, and stained in
10% Giemsa stain. Parasite burden was determined microscopically, and Leishman-Donovan units
(LDU) were calculated by the formula no. of parasites per host cell nucleus  organ weight in mg
as described previously (44). Microscopic evaluation of impression smears was carried out by a
scientist unaware of the treatment allocation.
Processing of samples for drug quantiﬁcation. Samples were thawed at room temperature
immediately prior to processing. Livers and spleens were homogenized with an equal volume of
zirconium oxide (ZrO) beads in 4 volumes of 0.1% aqueous formic acid in a Bullet blender (Next Advance,
United Kingdom). For control matrix samples plus internal standard (IS), calibration standards, quality
control (QC) samples, and study samples, 50 l of tissue homogenate or plasma was diluted with 250 l
IS solution (200 ng/ml tolbutamide in an 84:16 [vol/vol] mixture of methanol-DMSO). For blank samples
(matrix sample without IS), 50 l of tissue homogenate or plasma was diluted with an 84:16 (vol/vol)
mixture of methanol-DMSO. After shaking for 10 min at 200 rpm at room temperature, dilutions were
centrifuged at 4,150  g for 15 min at 4°C. Supernatants were transferred to 96-well plates and stored
at 80°C.
Preparation of calibration standards and QC samples. An amphotericin B stock solution (1.0
mg/ml) was prepared in DMSO, and from that standard, spiking solutions were prepared by serial
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dilution in 1% SDS in water. Calibration standards at a minimum of 6 concentrations were prepared by
mixing 5 l of the spiking solutions with 45 l of blank tissue homogenate or plasma, with the matrix
matching that of the study samples to be analyzed. QC samples at selected concentrations were
prepared in replicates in a similar fashion, and all samples were processed as described above.
Preparation of study samples. Concentrations of amphotericin B in study samples varied widely,
depending upon dosing and sampling regimens. Those samples expected to contain high concentra-
tions of amphotericin B were diluted with the matching control matrix by a suitable factor to reduce their
concentration into a quantiﬁable range (i.e., within the range of calibration standard concentrations).
LC-MS analytical conditions. All samples were analyzed using an Agilent 1200 high-performance
liquid chromatograph combined with an Agilent 6410A triple quadrupole mass spectrometer (both
Agilent, United Kingdom). A mobile phase of water–0.1% formic acid (channel A) and methanol–0.1%
formic acid (channel B) was used to elute sample components from a Kinetex column packed with 5-m
XB-C18 material (2.1 mm by 50 mm at 50°C; Phenomenex, United Kingdom). The mobile phase
composition was initially 20% B, programmed to increase linearly to 90% B at 1.60 min after
injection; after 0.4 min at 90% B, the composition was returned to its initial 20% B at 2.10 min
postinjection. Amphotericin B was detected by monitoring the transition from m/z 906.5 to m/z
743.2, the dehydrated protonated molecule at m/z 906.5 being the most intense ion produced for
this component in the ion source.
Analyte concentrations were quantiﬁed against calibration standards prepared in matched control
matrix, with aliquots of sample and standard being injected typically in the range 1 to 5 l, depending
on the expected study sample concentration.
Pharmacokinetic analysis. Noncompartmental analysis (NCA) was performed with Phoenix Win
Nonlin v6.3 (Certara, United Kingdom).
Characterization of serum protein proﬁles. Blood was collected from L. donovani-infected or
uninfected BALB/c mice by cardiac puncture under terminal anesthesia and stored overnight at 4°C.
Serum was harvested by centrifugation at 1,500  g at 4°C for 15 min and stored at 80°C prior to
analysis. Capillary electrophoresis and protein determinations were carried out by Laboklin GmbH & Co.
KG (Bad Kissingen, Germany).
Statistical analysis. Statistical signiﬁcance between two groups was evaluated by a t test, and that
between more than two groups was analyzed by one-way analysis of variance (ANOVA) assuming a
Gaussian distribution, followed by Sidak’s multiple-comparison test for selected groups as applicable
(GraphPad Prism 6). A P value of 0.05 was considered statistically signiﬁcant.
Ethical statement. Experiments involving animals were carried out under license in accordance with
the Animals (Scientiﬁc Procedures) Act of 1986 (UK Home Ofﬁce Project Licenses PPL70/6997 and
PPL70/8207) following approval by the Animal Welfare and Ethics Review Board at LSHTM.
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